Based O O
on O O
its O O
minimal O O
extent O O
of O O
absorption O O
interactions O O
of O O
PROTOPIC B-Brand O
Ointment O O
with O O
systemically O O
administered O O
drugs O O
are O O
unlikely O O
to O O
occur O O
but O O
can O O
not O O
be O O
ruled O O
out O O
. O O

Formal O O
topical O O
drug O O
interaction O O
studies O O
with O O
PROTOPIC B-Brand O
Ointment O O
have O O
not O O
been O O
conducted O O
. O O

Some O O
examples O O
of O O
such O O
drugs O O
are O O
erythromycin B-Drug O
itraconazole B-Drug B-Drug
ketoconazole B-Drug B-Drug
fluconazole B-Drug B-Drug
calcium B-Group O
channel I-Group O
blockers I-Group O
and O O
cimetidine B-Drug O
. O O

The O O
concomitant O O
administration O O
of O O
known O O
CYP9A9 O O
inhibitors O O
in O O
patients O O
with O O
widespread O O
and O O
/ O O
or O O
erythrodermic O O
disease O O
should O O
be O O
done O O
with O O
caution O O
. O O

Alcohol B-Drug O
( O O
this O O
combination O O
may O O
make O O
you O O
very O O
sick O O
) O O
and O O
primaquine B-Drug O

Interactions O O
Interaction O O
may O O
occur O O
with O O
Antacids B-Group O
Calcium B-Drug O
supplements O O
Cholestyramine B-Drug O
Choline B-Drug O
and O O
magnesium B-Drug O
salicylates I-Drug O
Colestipol B-Drug O
Iron B-Drug O
- O O
containing O O
drugs O O
Laxatives B-Group O
Magnesium B-Drug O
salicylate I-Drug O
: O O
these O O
drugs O O
may O O
decrease O O
the O O
potency O O
of O O
tetracyclines B-Group O
. O O

No O O
specific O O
interactions O O
are O O
known O O
at O O
this O O
time O O
. O O

Drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
LUCENTIS B-Brand O
. O O

No O O
formal O O
drug O O
- O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Vectibix B-Brand O
. O O

Drug O O
/ O O
Laboratory O O
Interactions O O
: O O
There O O
have O O
been O O
no O O
formal O O
drug O O
interaction O O
studies O O
performed O O
with O O
RITUXAN B-Brand O
. O O

Concomitant O O
Therapy O O
Special O O
care O O
should O O
be O O
exercised O O
in O O
treating O O
patients O O
who O O
are O O
receiving O O
concomitant O O
therapy O O
( O O
either O O
topically O O
or O O
systemically O O
) O O
with O O
known O O
photosensitizing O O
agents O O
such O O
as O O
anthralin B-Drug O
coal B-Drug_n O
tar I-Drug_n O
or O O
coal B-Drug_n O
tar I-Drug_n O
derivatives I-Drug_n O
griseofulvin B-Drug O
phenothiazines B-Group O
nalidixic B-Drug O
acid I-Drug O
halogenated B-Group O
salicylanilides I-Group O
( O O
bacteriostatic O O
soaps O O
) O O
sulfonamides B-Drug O
tetracyclines B-Group O
thiazides B-Group O
and O O
certain O O
organic O O
staining O O
dyes O O
such O O
as O O
methylene B-Drug_n O
blue I-Drug_n O
toluidine B-Drug_n O
blue I-Drug_n O
rose O O
bengal O O
and O O
methyl O O
orange O O
. O O

In O O
controlled O O
clinical O O
trials O O
ALOXI B-Brand O
injection O O
has O O
been O O
safely O O
administered O O
with O O
corticosteroids B-Group O
analgesics B-Group O
antiemetics B-Group O
/ O O
antinauseants B-Group O
antispasmodics B-Group O
and O O
anticholinergic B-Group O
agents I-Group O
. O O

Palonosetron B-Drug O
did O O
not O O
inhibit O O
the O O
antitumor O O
activity O O
of O O
the O O
five O O
chemotherapeutic B-Group O
agents I-Group O
tested O O
( O O
cisplatin B-Drug O
cyclophosphamide B-Drug B-Drug
cytarabine B-Drug B-Drug
doxorubicin B-Drug B-Drug
and O O
mitomycin B-Drug O
C I-Drug O
) O O
in O O
murine O O
tumor O O
models O O
. O O

Palonosetron B-Drug O
is O O
eliminated O O
from O O
the O O
body O O
through O O
both O O
renal O O
excretion O O
and O O
metabolic O O
pathways O O
with O O
the O O
latter O O
mediated O O
via O O
multiple O O
CYP O O
enzymes O O
. O O

In O O
vitro O O
studies O O
indicated O O
that O O
palonosetron B-Drug O
is O O
not O O
an O O
inhibitor O O
of O O
CYP9A9 O O
CYP9A9 O O
CYP9B9 O O
CYP9C9 O O
CYP9D9 O O
CYP9E9 O O
and O O
CYP9A9 O O
/ O O
9 O O
( O O
CYP9C9 O O
was O O
not O O
investigated O O
) O O
nor O O
does O O
it O O
induce O O
the O O
activity O O
of O O
CYP9A9 O O
CYP9D9 O O
or O O
CYP9A9 O O
/ O O
9 O O
. O O

Therefore O O
the O O
potential O O
for O O
clinically O O
significant O O
drug O O
interactions O O
with O O
palonosetron B-Drug O
appears O O
to O O
be O O
low O O
. O O

Potential O O
drug O O
interactions O O
between O O
OXISTAT B-Brand O
and O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

Although O O
no O O
drug O O
/ O O
drug O O
interactions O O
were O O
discovered O O
during O O
the O O
clinical O O
trials O O
of O O
MARINOL B-Brand O
Capsules O O
cannabinoids B-Group O
may O O
interact O O
with O O
other O O
medications O O
through O O
both O O
metabolic O O
and O O
pharmacodynamic O O
mechanisms O O
. O O

Two O O
early O O
clinical O O
studies O O
conducted O O
in O O
patients O O
who O O
received O O
Macugen B-Brand O
alone O O
and O O
in O O
combination O O
with O O
PDT O O
revealed O O
no O O
apparent O O
difference O O
in O O
the O O
plasma O O
pharmacokinetics O O
of O O
pegaptanib B-Drug O
. O O

Interactions O O
for O O
Dronabinol B-Drug O
: O O
In O O
studies O O
involving O O
patients O O
with O O
AIDS O O
and O O
/ O O
or O O
cancer O O
MARINOL B-Brand O
( O O
Dronabinol B-Drug O
) O O
Capsules O O
has O O
been O O
co O O
- O O
administered O O
with O O
a O O
variety O O
of O O
medications O O
( O O
e.g. O O
cytotoxic O O
agents O O
anti B-Drug O
- O O
infective B-Drug O
agents O O
sedatives B-Group O
or O O
opioid B-Group O
analgesics I-Group O
) O O
without O O
resulting O O
in O O
any O O
clinically O O
significant O O
drug O O
/ O O
drug O O
interactions O O
. O O

The O O
concomitant O O
administration O O
of O O
known O O
CYP9A O O
family O O
of O O
inhibitors O O
in O O
patients O O
with O O
widespread O O
and O O
/ O O
or O O
erythrodermic O O
disease O O
should O O
be O O
done O O
with O O
caution O O
. O O

Some O O
examples O O
of O O
such O O
drugs O O
are O O
erythromycin B-Drug O
itraconazole B-Drug B-Drug
ketoconazole B-Drug B-Drug
fluconazole B-Drug B-Drug
calcium B-Group O
channel I-Group O
blockers I-Group O
and O O
cimetidine B-Drug O
. O O

Potential O O
interactions O O
between O O
Elidel B-Brand O
and O O
other O O
drugs O O
including O O
immunizations O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

Due O O
to O O
the O O
very O O
low O O
blood O O
levels O O
of O O
pimecrolimus B-Drug O
detected O O
in O O
some O O
patients O O
after O O
topical O O
application O O
systemic O O
drug O O
interactions O O
are O O
not O O
expected O O
but O O
can O O
not O O
be O O
ruled O O
out O O
. O O

Since O O
there O O
is O O
no O O
interaction O O
with O O
theophylline B-Drug O
interaction O O
with O O
other O O
methylxanthines B-Group O
such O O
as O O
caffeine B-Drug O
is O O
unlikely O O
. O O

However O O
renal O O
toxicity O O
was O O
seen O O
with O O
this O O
drug O O
in O O
combination O O
with O O
cisplatin B-Drug O
in O O
clinical O O
trials O O
. O O

Digoxin B-Drug O
: O O
Sparfloxacin B-Drug O
has O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-Drug O
. O O

Methylxanthines B-Group O
: O O
Sparfloxacin B-Drug O
does O O
not O O
increase O O
plasma O O
theophylline B-Drug B-Drug
concentrations O O
. O O

Although O O
this O O
displacement O O
has O O
not O O
been O O
confirmed O O
in O O
vivo O O
practitioners O O
should O O
monitor O O
patients O O
for O O
a O O
change O O
in O O
dosage O O
requirements O O
when O O
administering O O
dronabinol B-Drug O
to O O
patients O O
receiving O O
other O O
highly O O
protein O O
- O O
bound O O
drugs O O
. O O

Dronabinol B-Drug O
is O O
highly O O
protein O O
bound O O
to O O
plasma O O
proteins O O
and O O
therefore O O
might O O
displace O O
other O O
protein O O
- O O
bound O O
drugs O O
. O O

Cimetidine B-Drug B-Drug
: O O
Cimetidine B-Drug O
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
sparfloxacin B-Drug O
. O O

The O O
oral O O
bioavailability O O
of O O
sparfloxacin B-Drug O
is O O
not O O
reduced O O
when O O
the O O
aluminum B-Drug O
- O O
magnesium B-Drug O
suspension O O
is O O
administered O O
9 O O
hours O O
following O O
sparfloxacin O O
administration O O
. O O

Zinc B-Drug O
/ O O
iron B-Drug O
salts O O
: O O
Absorption O O
of O O
quinolones B-Group O
is O O
reduced O O
significantly O O
by O O
these O O
preparations O O
. O O

These O O
products O O
may O O
be O O
taken O O
9 O O
hours O O
after O O
sparfloxacin B-Drug O
administration O O
. O O

Probenecid B-Drug O
: O O
Probenecid B-Drug O
does O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
sparfloxacin B-Drug O
. O O

However O O
because O O
telbivudine B-Drug O
is O O
eliminated O O
primarily O O
by O O
renal O O
excretion O O
co O O
administration O O
of O O
telbivudine B-Drug O
with O O
drugs O O
that O O
alter O O
renal O O
function O O
may O O
alter O O
plasma O O
concentrations O O
of O O
telbivudine B-Drug O
. O O

Telbivudine B-Drug B-Drug
is O O
excreted O O
mainly O O
by O O
passive O O
diffusion O O
so O O
the O O
potential O O
for O O
interactions O O
between O O
telbivudine B-Drug O
and O O
other O O
drugs O O
eliminated O O
by O O
renal O O
excretion O O
is O O
low O O
. O O

Caution O O
is O O
indicated O O
when O O
Aredia B-Brand O
is O O
used O O
with O O
other O O
potentially O O
nephrotoxic O O
drugs O O
. O O

Therefore O O
furosemide B-Drug O
should O O
not O O
be O O
administered O O
in O O
intravenous O O
lines O O
containing O O
PRIMACOR B-Brand O
. O O

Chemical O O
Interactions O O
There O O
is O O
an O O
immediate O O
chemical O O
interaction O O
which O O
is O O
evidenced O O
by O O
the O O
formation O O
of O O
a O O
precipitate O O
when O O
furosemide B-Drug O
is O O
injected O O
into O O
an O O
intravenous O O
line O O
of O O
an O O
infusion O O
of O O
PRIMACOR B-Brand O
. O O

May O O
interact O O
with O O
cimetidine B-Drug O
digoxin B-Drug O
medicines O O
to O O
control O O
heart O O
rhythm O O
sevelamer B-Drug O
and O O
theophylline B-Drug O
. O O

The O O
interaction O O
may O O
result O O
from O O
reduced O O
absorption O O
of O O
phenytoin B-Drug O
and O O
an O O
increase O O
in O O
the O O
rate O O
of O O
its O O
metabolism O O
and O O
elimination O O
. O O

captopril B-Drug O
; O O

chlorthalidone B-Drug B-Drug
furosemide B-Drug O
hydrochlorothiazide B-Drug B-Drug
spironolactone B-Drug B-Drug
; O O

and O O
potassium B-Drug O
supplements O O
. O O

heparin B-Drug O
warfarin B-Drug O
diazepam B-Drug O
insulin B-Drug O
; O O

Twelve O O
of O O
9 O O
( O O
9 O O
% O O
) O O
patients O O
developed O O
serious O O
intraocular O O
inflammation O O
; O O

in O O
9 O O
of O O
the O O
9 O O
patients O O
this O O
occurred O O
when O O
LUCENTIS B-Brand O
was O O
administered O O
9 O O
days O O
( O O
9 O O
days O O
) O O
after O O
verteporfin B-Drug O
PDT O O
. O O

isosorbide B-Drug O
dinitrate I-Drug O
nitroglycerin B-Drug O
; O O

hydralazine B-Drug B-Drug
prazosin B-Drug O
; O O

- O O
Antacids B-Group O
- O O
Diarrhea O O
medicine O O
containing O O
kaolin B-Drug O
or O O
attapulgite B-Drug O
- O O
Ketoconazole B-Drug O
- O O
Central B-Group O
nervous I-Group O
system I-Group O
CNS I-Group O
depressants I-Group O
- O O
Other O O
anticholinergics B-Group O
- O O
Tricyclic B-Group O
antidepressants I-Group O
( O O
e.g. O O
Elavil B-Brand O
Asendin B-Brand O
Anafranil B-Brand O
Pertofrane B-Brand O
Sinequan B-Brand O
Tofranil B-Brand O
Aventyl B-Brand O
Surmontil B-Brand O
) O O
- O O
Potassium B-Drug O
chloride I-Drug O
( O O
e.g. O O
Kay B-Brand O
Ciel I-Brand O
) O O

Drug O O
Interactions O O
: O O
Pirenzepine B-Drug O
may O O
interact O O
with O O
the O O
following O O
drugs O O
which O O
may O O
affect O O
the O O
effect O O
of O O
Pirenzepine B-Drug O
or O O
whose O O
effects O O
may O O
be O O
affected O O
. O O

Consult O O
your O O
doctor O O
or O O
pharmacist O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
: O O
seizure O O
medications O O
antibiotics B-Group B-Drug
warfarin B-Drug B-Drug
medications O O
to O O
help O O
you O O
sleep O O

Drug O O
/ O O
Laboratory O O
Test O O
Interaction O O
: O O
The O O
concomitant O O
use O O
of O O
anticholinergic B-Group O
agents I-Group O
may O O
make O O
patients O O
hyporesponsive O O
i.e O O
. O O

may O O
produce O O
a O O
false O O
positive O O
result O O
. O O

Talk O O
to O O
your O O
pharmacist O O
for O O
more O O
information O O
. O O

Drug O O
Interactions O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
- O O
This O O
medicine O O
may O O
be O O
affected O O
by O O
the O O
drug O O
cholestyramine B-Drug O
and O O
should O O
not O O
be O O
taken O O
with O O
any O O
form O O
of O O
estrogen O O
therapy O O
. O O

If O O
you O O
are O O
taking O O
these O O
medicines O O
together O O
or O O
you O O
have O O
further O O
questions O O
about O O
drug O O
interactions O O
talk O O
to O O
your O O
doctor O O
or O O
pharmacist O O
. O O

Drugs O O
that O O
may O O
decrease O O
the O O
effects O O
of O O
this O O
medicine O O
include O O
: O O
Rifampin B-Drug O
barbiturates B-Group O
phenytoin B-Drug B-Drug
( O O
Dilantin B-Brand O
) O O
carbamazepine B-Drug O
( O O
Tegretol B-Brand O
) O O
Estrogens B-Group O
may O O
decrease O O
the O O
effects O O
of O O
benzodiazepines B-Group O
( O O
lorezepam B-Drug O
oxezepam B-Drug O
temezepam B-Drug O
) O O
. O O

There O O
have O O
been O O
no O O
formal O O
interaction O O
studies O O
of O O
PHOTOFRIN B-Brand O
and O O
any O O
other O O
drugs O O
. O O

However O O
it O O
is O O
possible O O
that O O
concomitant O O
use O O
of O O
other O O
photosensitizing B-Group O
agents I-Group O
( O O
e.g. O O
tetracyclines B-Group O
sulfonamides B-Group O
phenothiazines B-Group O
sulfonylurea B-Group O
hypoglycemia O O
agents O O
thiazide B-Group O
diuretics I-Group O
and O O
griseofulvin B-Drug O
) O O
could O O
increase O O
the O O
photosensitivity O O
reaction O O
. O O

PHOTOFRIN B-Brand B-Drug
PDT O O
causes O O
direct O O
intracellular O O
damage O O
by O O
initiating O O
radical O O
chain O O
reactions O O
that O O
damage O O
intracellular O O
membranes O O
and O O
mitochondria O O
. O O

Tissue O O
damage O O
also O O
results O O
from O O
ischemia O O
secondary O O
to O O
vasoconstriction O O
platelet O O
activation O O
and O O
aggregation O O
and O O
clotting O O
. O O

Research O O
in O O
animals O O
and O O
in O O
cell O O
culture O O
has O O
suggested O O
that O O
many O O
drugs O O
could O O
influence O O
the O O
effects O O
of O O
PDT O O
possible O O
examples O O
of O O
which O O
are O O
described O O
below O O
. O O

There O O
are O O
no O O
human O O
data O O
that O O
support O O
or O O
rebut O O
these O O
possibilities O O
. O O

Compounds O O
that O O
quench O O
active O O
oxygen O O
species O O
or O O
scavenge O O
radicals O O
such O O
as O O
dimethyl B-Drug_n O
sufloxide I-Drug_n O
b B-Drug O
- O O
carotene B-Drug O
ethanol B-Drug O
formate B-Drug_n O
and O O
mannitol B-Drug O
would O O
be O O
expected O O
to O O
decrease O O
PDT O O
activity O O
. O O

No O O
formal O O
drug O O
- O O
drug O O
interaction O O
studies O O
were O O
conducted O O
. O O

Drugs O O
that O O
decrease O O
clotting O O
vasoconstriction O O
or O O
platelet O O
aggregation O O
e.g. O O
thromboxane O O
A9 O O
inhibitors O O
could O O
decrease O O
the O O
efficacy O O
of O O
PDT O O
. O O

Glucocorticoid B-Group O
hormones O O
given O O
before O O
or O O
concomitant O O
with O O
PDT O O
may O O
decrease O O
the O O
efficacy O O
of O O
the O O
treatment O O
. O O

Preclinical O O
data O O
also O O
suggest O O
that O O
tissue O O
ischemia O O
allopurinol B-Drug O
calcium B-Group O
channel I-Group O
blockers I-Group O
and O O
some O O
prostaglandin O O
synthesis O O
inhibitors O O
could O O
interfere O O
with O O
PHOTOFRIN O O
PDT O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Infergen B-Brand O
. O O

Infergen B-Brand O
should O O
be O O
used O O
cautiously O O
in O O
patients O O
who O O
are O O
receiving O O
agents O O
that O O
are O O
known O O
to O O
cause O O
myelosuppression O O
or O O
with O O
agents O O
known O O
to O O
be O O
metabolized O O
via O O
the O O
cytochrome O O
P O O
- O O
9 O O
pathway.9 O O
Patients O O
taking O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
pathway O O
should O O
be O O
monitored O O
closely O O
for O O
changes O O
in O O
the O O
therapeutic O O
and O O
/ O O
or O O
toxic O O
levels O O
of O O
concomitant O O
drugs O O
. O O

However O O
formal O O
drug O O
interactions O O
studies O O
have O O
not O O
been O O
conducted O O
. O O

Concomitant O O
glucocorticoid O O
therapy O O
may O O
inhibit O O
the O O
response O O
to O O
Geref B-Brand O
. O O
There O O
was O O
no O O
evidence O O
in O O
the O O
controlled O O
studies O O
of O O
Geref B-Brand O
's O O
interaction O O
with O O
drugs O O
commonly O O
used O O
in O O
the O O
treatment O O
of O O
routine O O
pediatric O O
problems O O
/ O O
illnesses O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
Administration O O
of O O
the O O
BEXXAR B-Brand O
therapeutic O O
regimen O O
may O O
result O O
in O O
the O O
development O O
of O O
human O O
anti O O
- O O
murine O O
antibodies O O
( O O
HAMA O O
) O O
. O O

The O O
presence O O
of O O
HAMA O O
may O O
affect O O
the O O
accuracy O O
of O O
the O O
results O O
of O O
in O O
vitro O O
and O O
in O O
vivo O O
diagnostic O O
tests O O
and O O
may O O
affect O O
the O O
toxicity O O
profile O O
and O O
efficacy O O
of O O
therapeutic O O
agents O O
that O O
rely O O
on O O
murine O O
antibody O O
technology O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Due O O
to O O
the O O
frequent O O
occurrence O O
of O O
severe O O
and O O
prolonged O O
thrombocytopenia O O
the O O
potential O O
benefits O O
of O O
medications O O
that O O
interfere O O
with O O
platelet O O
function O O
and O O
/ O O
or O O
anticoagulation O O
should O O
be O O
weighed O O
against O O
the O O
potential O O
increased O O
risk O O
of O O
bleeding O O
and O O
hemorrhage O O
. O O

Therefore O O
warfarin B-Drug O
dose O O
changes O O
and O O
monitoring O O
for O O
the O O
effects O O
of O O
warfarin B-Drug O
on O O
blood O O
clotting O O
are O O
necessary O O
. O O

Patients O O
who O O
are O O
HAMA O O
positive O O
may O O
be O O
at O O
increased O O
risk O O
for O O
serious O O
allergic O O
reactions O O
and O O
other O O
side O O
effects O O
if O O
they O O
undergo O O
in O O
vivo O O
diagnostic O O
testing O O
or O O
treatment O O
with O O
murine B-Group O
monoclonal I-Group O
antibodies I-Group O
. O O

Heparin B-Drug O
should O O
not O O
be O O
included O O
in O O
the O O
same O O
syringe O O
as O O
Sodium B-Drug O
Tetradecyl I-Drug O
Sulfate I-Drug O
since O O
the O O
two O O
are O O
incompatible O O
. O O

The O O
physician O O
must O O
use O O
judgment O O
and O O
evaluate O O
any O O
patient O O
taking O O
antiovulatory O O
drugs O O
prior O O
to O O
initiating O O
treatment O O
with O O
Sotradecol B-Brand O
. O O

Interactions O O
for O O
Sodium B-Drug O
Tetradecyl I-Drug O
Sulfate I-Drug O
: O O
No O O
well O O
- O O
controlled O O
studies O O
have O O
been O O
performed O O
on O O
patients O O
taking O O
antiovulatory O O
agents O O
. O O

In O O
Trial O O
9 O O
the O O
proportions O O
of O O
patients O O
in O O
the O O
placebo O O
and O O
Synagis B-Brand O
groups O O
who O O
received O O
routine O O
childhood O O
vaccines B-Group O
influenza B-Group O
vaccine I-Group O
bronchodilators B-Group O
or O O
corticosteroids B-Group O
were O O
similar O O
and O O
no O O
incremental O O
increase O O
in O O
adverse O O
reactions O O
was O O
observed O O
among O O
patients O O
receiving O O
these O O
agents O O
. O O

The O O
pharmacokinetic O O
profile O O
of O O
temazepam B-Drug O
does O O
not O O
appear O O
to O O
be O O
altered O O
by O O
orally O O
administered O O
cimetidine B-Drug O
dosed O O
according O O
to O O
labeling O O
. O O

TERAZOL B-Brand O
9 O O
Vaginal O O
Cream O O
9 O O
% O O
and O O
TERAZOL B-Brand O
9 O O
Vaginal O O
Suppositories O O
9 O O
mg O O
The O O
therapeutic O O
effect O O
of O O
these O O
products O O
is O O
not O O
affected O O
by O O
oral O O
contraceptive B-Group O
usage O O
. O O

TERAZOL B-Brand O
9 O O
Vaginal O O
Cream O O
9 O O
% O O
The O O
levels O O
of O O
estradiol B-Drug O
( O O
E9 O O
) O O
and O O
progesterone B-Drug O
did O O
not O O
differ O O
significantly O O
when O O
9 O O
% O O
terconazole B-Drug O
vaginal O O
cream O O
was O O
administered O O
to O O
healthy O O
female O O
volunteers O O
established O O
on O O
a O O
low O O
dose O O
oral O O
contraceptive B-Group O
. O O

Drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
Macugen B-Brand O
. O O

There O O
are O O
as O O
yet O O
no O O
known O O
drug O O
interactions O O
but O O
further O O
study O O
is O O
required O O
. O O

No O O
data O O
are O O
available O O
regarding O O
interaction O O
of O O
BILTRICIDE B-Brand O
with O O
other O O
drugs O O
. O O

This O O
medicine O O
is O O
generally O O
safe O O
with O O
other O O
medications O O
but O O
patient O O
should O O
consult O O
doctor O O
or O O
pharmacist O O
if O O
patient O O
is O O
taking O O
a O O
blood O O
thinner O O
( O O
anticoagulant B-Group O
) O O
cyclosporin B-Drug O
phenytoin B-Drug O
or O O
methotrexate B-Drug O
. O O

Because O O
systemic O O
exposure O O
to O O
Valstar B-Brand O
is O O
negligible O O
following O O
intravesical O O
administration O O
the O O
potential O O
for O O
drug O O
interactions O O
is O O
low O O
. O O

Maternal O O
sinus O O
bradycardia O O
with O O
abnormal O O
atrioventricular O O
rhythms O O
has O O
also O O
been O O
noted O O
when O O
oxytocin B-Drug O
was O O
used O O
concomitantly O O
with O O
cyclopropane O O
anesthesia O O
. O O

Misoprostol B-Drug O
does O O
not O O
exert O O
clinically O O
significant O O
effects O O
on O O
the O O
absorption O O
blood O O
levels O O
and O O
anti O O
- O O
platelet O O
effects O O
of O O
therapeutic O O
doses O O
of O O
aspirin B-Brand O
. O O

9 O O

Pyrazinamide B-Drug B-Drug
has O O
been O O
reported O O
to O O
interfere O O
with O O
ACETEST O O
and O O
KETOSTIX O O
urine O O
tests O O
to O O
produce O O
a O O
pink O O
- O O
brown O O
color O O
. O O

Severe O O
hypertension O O
has O O
been O O
reported O O
when O O
oxytocin B-Drug O
was O O
given O O
three O O
to O O
four O O
hours O O
following O O
prophylactic O O
administration O O
of O O
a O O
vasoconstrictor B-Group O
in O O
conjunction O O
with O O
caudal O O
block O O
anesthesia O O
. O O

Drug O O
/ O O
Laboratory O O
Test O O
Interactions O O
: O O
Potential O O
interactions O O
between O O
ERTACZOTM B-Brand O
Cream O O
9 O O
% O O
and O O
other O O
drugs O O
or O O
laboratory O O
tests O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

Combined O O
usage O O
of O O
MAO B-Group O
inhibitors I-Group O
should O O
be O O
avoided O O

Cyclopropane O B-Drug
anesthesia O O
may O O
modify O O
oxytocin B-Drug O
cardiovascular O O
effects O O
so O O
as O O
to O O
produce O O
unexpected O O
results O O
such O O
as O O
hypotension O O
. O O

thus O O
interactions O O
with O O
drugs O O
that O O
inhibit O O
induce O O
or O O
are O O
metabolized O O
by O O
those O O
enzymes O O
are O O
not O O
expected O O
. O O

Olmesartan B-Drug O
medoxomil I-Drug O
is O O
not O O
metabolized O O
by O O
the O O
cytochrome O O
P9 O O
system O O
and O O
has O O
no O O
effects O O
on O O
P9 O O
enzymes O O
; O O

The O O
bioavailability O O
of O O
olmesartan B-Drug O
was O O
not O O
significantly O O
altered O O
by O O
the O O
co O O
- O O
administration O O
of O O
antacids B-Group O
[ O O
Al O O
( O O
OH O O
) O O
9 O O
/ O O
Mg O O
( O O
OH O O
) O O
9 O O
] O O
. O O

No O O
significant O O
drug O O
interactions O O
were O O
reported O O
in O O
studies O O
in O O
which O O
olmesartan B-Drug O
medoxomil I-Drug O
was O O
co O O
- O O
administered O O
with O O
digoxin B-Drug O
or O O
warfarin B-Drug O
in O O
healthy O O
volunteers O O
. O O

There O O
are O O
so O O
far O O
no O O
reported O O
adverse O O
interactions O O
with O O
SAMe B-Drug O
and O O
other O O
drugs O O
dietary O O
supplements O O
or O O
foods O O
. O O

A O O
study O O
in O O
healthy O O
volunteers O O
involving O O
single O O
- O O
dose O O
IV O O
palonosetron B-Drug O
( O O
9 O O
mg O O
) O O
and O O
steady O O
state O O
oral O O
metoclopramide B-Drug O
( O O
9 O O
mg O O
four O O
times O O
daily O O
) O O
demonstrated O O
no O O
significant O O
pharmacokinetic O O
interaction O O
. O O

Remifentanil B-Drug B-Drug
clearance O O
is O O
not O O
altered O O
by O O
concomitant O O
administration O O
of O O
thiopental B-Drug O
isoflurane B-Drug O
propofol B-Drug O
or O O
temazepam B-Drug O
during O O
anesthesia O O
. O O

In O O
animals O O
the O O
duration O O
of O O
muscle O O
paralysis O O
from O O
succinylcholine B-Drug O
is O O
not O O
prolonged O O
by O O
remifentanil B-Drug O
. O O

In O O
vitro O O
studies O O
with O O
atracurium B-Drug O
mivacurium B-Drug O
esmolol B-Drug O
echothiophate B-Drug B-Drug
neostigmine B-Drug B-Drug
physostigmine B-Drug B-Drug
and O O
midazolam B-Drug O
revealed O O
no O O
inhibition O O
of O O
remifentanil B-Drug O
hydrolysis O O
in O O
whole O O
human O O
blood O O
by O O
these O O
drugs O O
. O O

Drug O O
- O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
VIGAMOX B-Brand O
solution O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
moxifloxacin B-Drug O
does O O
not O O
inhibit O O
CYP9A9 O O
CYP9D9 O O
CYP9C9 O O
CYP9C9 O O
or O O
CYP9A9 O O
indicating O O
that O O
moxifloxacin B-Drug O
is O O
unlikely O O
to O O
alter O O
the O O
pharmacokinetics O O
of O O
drugs O O
metabolized O O
by O O
these O O
cytochrome O O
P9 O O
isozymes O O
. O O

Clinical O O
studies O O
of O O
interactions O O
of O O
VIRAZOLE B-Brand O
with O O
other O O
drugs O O
commonly O O
used O O
to O O
treat O O
infants O O
with O O
RSV O O
infections O O
such O O
as O O
digoxin B-Drug O
bronchodilators B-Group O
other O O
antiviral B-Group O
agents I-Group O
antibiotics B-Group O
or O O
anti B-Group O
- O O
metabolites B-Group O
have O O
not O O
been O O
conducted O O
. O O

Interference O O
by O O
VIRAZOLE B-Brand O
with O O
laboratory O O
tests O O
has O O
not O O
been O O
evaluated O O
. O O

Misoprostol B-Drug O
has O O
no O O
clinically O O
significant O O
effect O O
on O O
the O O
kinetics O O
of O O
diclofenac B-Drug O
or O O
ibuprofen B-Drug O
. O O

Interactions O O
with O O
cylcopholsphamide O O
fludarabine B-Drug B-Drug
and O O
vidarabine B-Drug O

In O O
vivo O O
drug O O
- O O
drug O O
interaction O O
studies O O
have O O
suggested O O
that O O
pioglitazone B-Drug O
may O O
be O O
a O O
weak O O
inducer O O
of O O
CYP O O
9 O O
isoform O O
9A9 O O
substrate O O
. O O

Pegaptanib B-Drug O
is O O
metabolized O O
by O O
nucleases O O
and O O
is O O
generally O O
not O O
affected O O
by O O
the O O
cytochrome O O
P9 O O
system O O
. O O

lidocaine B-Drug B-Drug
quinidine B-Drug B-Drug
; O O

No O O
untoward O O
clinical O O
manifestations O O
have O O
been O O
observed O O
in O O
limited O O
experience O O
with O O
patients O O
in O O
whom O O
PRIMACOR B-Brand O
was O O
used O O
concurrently O O
with O O
the O O
following O O
drugs O O
: O O
digitalis B-Group O
glycosides I-Group O
; O O

- O O
Increased O O
action O O
of O O
oral O O
anticoagulants B-Group O
. O O

- O O
Decreased O O
absorption O O
of O O
colestipol B-Drug O
cholestyramine B-Drug O
mineral B-Drug O
oil I-Drug O
and O O
sucralfate B-Drug O
. O O

False O O
- O O
positive O O
tests O O
may O O
occur O O
in O O
patients O O
with O O
hypertension O O
without O O
pheochromocytoma O O
. O O

Misoprostol B-Drug O
has O O
not O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
beneficial O O
effects O O
of O O
aspirin B-Brand O
on O O
signs O O
and O O
symptoms O O
of O O
rheumatoid O O
arthritis O O
. O O

Diagnosis O O
of O O
pheochromocytoma O O
- O O
phentolamine O O
blocking O O
test O O
. O O

The O O
test O O
is O O
most O O
reliable O O
in O O
detecting O O
pheochromocytoma O O
in O O
patients O O
with O O
sustained O O
hypertension O O
and O O
least O O
reliable O O
in O O
those O O
with O O
paroxysmal O O
hypertension O O
. O O

To O O
date O O
post O O
- O O
marketing O O
experience O O
has O O
not O O
revealed O O
any O O
significant O O
drug O O
interactions O O
in O O
patients O O
who O O
have O O
received O O
NOVANTRONE B-Brand O
for O O
treatment O O
of O O
cancer O O
. O O

Mitoxantrone B-Drug B-Drug
and O O
its O O
metabolites O O
are O O
excreted O O
in O O
bile O O
and O O
urine O O
but O O
it O O
is O O
not O O
known O O
whether O O
the O O
metabolic O O
or O O
excretory O O
pathways O O
are O O
saturable O O
may O O
be O O
inhibited O O
or O O
induced O O
or O O
if O O
mitoxantrone B-Drug O
and O O
its O O
metabolites O O
undergo O O
enterohepatic O O
circulation O O
. O O

Following O O
concurrent O O
administration O O
of O O
NOVANTRONE B-Brand O
with O O
corticosteroids B-Group O
no O O
evidence O O
of O O
drug O O
interactions O O
has O O
been O O
observed O O
. O O

Information O O
on O O
drug O O
interactions O O
in O O
patients O O
with O O
multiple O O
sclerosis O O
is O O
limited O O
. O O

Therefore O O
clinical O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
human O O
cytochrome O O
P9 O O
isoenzymes O O
are O O
not O O
expected O O
. O O

An O O
additional O O
clinical O O
drug O O
- O O
drug O O
interaction O O
study O O
showed O O
no O O
effect O O
of O O
rifaximin B-Drug O
on O O
the O O
presystemic O O
metabolism O O
of O O
an O O
oral O O
contraceptive B-Group O
containing O O
ethinyl B-Drug O
estradiol I-Drug O
and O O
norgestimate B-Drug O
. O O

Drug O O
- O O
Drug O O
Interactions O O
Although O O
in O O
vitro O O
studies O O
demonstrated O O
the O O
potential O O
of O O
rifaximin B-Drug O
to O O
interact O O
with O O
cytochrome O O
P9 O O
9A9 O O
( O O
CYP9A9 O O
) O O
a O O
clinical O O
drug O O
- O O
drug O O
interaction O O
study O O
demonstrated O O
that O O
rifaximin B-Drug O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
midazolam B-Drug O
either O O
presystemically O O
or O O
systemically O O
. O O

Concomitant O O
administration O O
of O O
a O O
loop B-Group O
diuretic I-Group O
had O O
no O O
effect O O
on O O
the O O
calcium O O
- O O
lowering O O
action O O
of O O
Aredia B-Brand O
. O O

Oral O O
contraceptives B-Group O
containing O O
estrogen B-Drug O
: O O
tetracyclines B-Group O
may O O
decrease O O
the O O
contraceptive O O
effect O O
and O O
increase O O
the O O
chance O O
of O O
unwanted O O
pregnancy O O
. O O

Not O O
compatible O O
with O O
CNS B-Group O
depressants I-Group O
or O O
trycyclic B-Group O
antidepressants I-Group O

The O O
contribution O O
of O O
vincristine B-Drug O
sulfate I-Drug O
to O O
this O O
interaction O O
is O O
not O O
certain O O
. O O

No O O
reported O O
significant O O
interactions O O

LUCENTIS B-Brand O
intravitreal O O
injection O O
has O O
been O O
used O O
adjunctively O O
with O O
verteporfin B-Drug O
photodynamic O O
therapy O O
( O O
PDT O O
) O O
. O O

May O O
increase O O
the O O
effect O O
of O O
oral O O
blood B-Group O
thinners I-Group O
for O O
example O O
warfarin B-Drug O
( O O
Coumadin B-Brand O
) O O
. O O

Warfarin B-Drug O
: O O
Sparfloxacin B-Drug O
does O O
not O O
increase O O
the O O
anti O O
- O O
coagulant O O
effect O O
of O O
warfarin B-Drug O
. O O

Dosage O O
adjustment O O
should O O
be O O
based O O
on O O
serial O O
blood O O
level O O
monitoring O O
. O O

Also O O
see O O
CLINICAL O O
PHARMACOLOGY O O

There O O
have O O
been O O
no O O
studies O O
of O O
the O O
interaction O O
of O O
methyl B-Drug O
aminolevulinate I-Drug O
cream O O
with O O
any O O
other O O
drugs O O
including O O
local O O
anesthetics B-Group O
. O O

It O O
is O O
possible O O
that O O
concomitant O O
use O O
of O O
other O O
known O O
photosensitizing O O
agents O O
might O O
increase O O
the O O
photosensitivity O O
reaction O O
of O O
actinic O O
keratoses O O
treated O O
with O O
methyl B-Drug O
aminolevulinate I-Drug O
cream O O
. O O

No O O
drug O O
interaction O O
studies O O
were O O
conducted O O
. O O
